Codexis

Portola Pharmaceuticals is a Bay Area–based pharmaceuticals company with a focus on bioresearch and drug development. Their efforts are directed towards global markets, specifically in the treatment of cardiovascular disease and inflammation. Generated from their available business information

XOMA is among the leaders in the discovery, development and manufacture of therapeutic antibodies. The company s broad technology platform, scientific expertise and integrated product development infrastructure extends from antibody discovery to regulatory approval. It is a proven development partner and technology licensor, receiving royalties from Genentech for Raptiva and Lucentis. XOMA s pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development. The company s operational infrastructure enables it to produce product candidates in compliance with cGMP using mammalian and microbial systems for preclinical and clinical purposes to meet the needs of many product development programs. Its additional capabilities include cell line development, process and assay creation, contract manufacturing and regulatory compliance. XOMA has operated for more than 25 years and has a location in Berkeley, Calif.